
Behavioral Health Assessment Using Vocal Biomarkers
January 29, 2026
This research white paper highlights the potential of vocal biomarkers as a scalable, non-invasive tool for detecting anxiety and depression, two of the most prevalent and under-treated mental health conditions worldwide. Using machine learning models trained on spontaneous speech, the study demonstrates how automated screening could help bridge critical gaps in mental healthcare, particularly for those without easy access to traditional diagnostic methods. The findings suggest that while vocal analysis alone is not yet a replacement for clinical evaluation, it serves as an effective first step in identifying at-risk individuals, prompting earlier intervention and reducing the burden on healthcare systems.
Reference: Namhee Kwon, Raymond Brueckner, Vinod Subramanian, Nate Blaylock, Henry O’Connell, “Behavioral Health Assessment Using Vocal Biomarkers,” January 2026.
Recent News
- BioUtah’s 2026 Utah Life Sciences Summit Recap
- 2026 Life Sciences Awards to be Presented at the Mayer Brown Utah Life Sciences Summit
- PROGRESS TRIAL DEMONSTRATES EDWARDS TAVR IS SUPERIOR TO CLINICAL SURVEILLANCE FOR MODERATE AS PATIENTS WITH AT-RISK FEATURES
- Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product
- Utah Business, Government Leaders Deepen Connections in Ireland
- Co-Diagnostics’ Joint Venture CoSara Diagnostics Announces Publication of Peer-Reviewed HPV Screening Study Using CoSara’s SARAGENE® Test














